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Abstract
Introduction Infections commonly complicate the course of
systemic lupus erythematosus (SLE). Our aim is to investigate
the clinical predictors of major infections in patients with SLE.
Methods A nested case–control study design was used within
the prospective Lupus-Cruces cohort. The endpoints of the
study were major infections. Cases were defined as patients
with a major infection. Two controls (SLE patients without major
infections), matched for time of follow-up until the event and age
at diagnosis, were selected for each case. Univariate analysis
and logistic regression models were used for the analysis of
data.
Results Two hundred and forty-nine patients (83 cases, 166
controls) were selected. Eighty-three episodes of major
infections were analyzed; E. coli, S. aureus, M. tuberculosis and
S. pneumoniae being the most frequent isolates. Univariate
analysis identified several variables related with infection: lung
and renal involvement, at or previous to the study point;
leukopenia at the study point; antiphospholipid antibody-
positivity and treatment with prednisone within 3 months
previous to the study point, and the dose of prednisone
received. Treatment with antimalarials, on the other hand,
showed a strong inverse association with major infections.
Logistic regression models identified treatment with
antimalarials (odds ratio (OR) = 0.06, 95% confidence interval
(CI) = 0.02 to 0.18), prednisone dose (OR = 1.12, 95% CI =
1.04 to 1.19) and lung involvement (OR = 4.41, 95% CI = 1.06
to 18.36) as significant and independent predictors of major
infections. No significant interactions among these three
variables were found. Further adjustment for potential
confounders related with antimalarial treatment did not change
the results.
Conclusions The risk of major infections in patients with SLE is
mostly influenced by treatment. Prednisone treatment, even at
moderate doses, increases the risk, whilst antimalarials have a
protective effect.
Introduction
Infections are among the most important causes of morbidity
and mortality in patients with systemic lupus erythematosus
(SLE) [1]. Several studies have analyzed the prevalence and
associated clinical and laboratory features of infection in SLE.
Disease duration, disease activity, leukopenia, steroids and
immunosuppressive drugs have been linked, in different com-
binations, to an increased risk of infection [2-9]. The definitions
of infection have been heterogeneous, however, with many
studies also including minor infections with low prognostic
implications. Moreover, while the role of prednisone, cyclo-
phosphamide and other immunosuppressive drugs has been
extensively analyzed, few studies included antimalarials among
the variables potentially influencing the risk of infection.
The aim of the present study is to identify the potential predic-
tors of infections in a prospective observational cohort of
patients with SLE, limiting the analysis to major episodes with
important clinical impact and including antimalarials among
the potential variables influencing the final outcome.
Materials and methods
Study design and patients
A nested case–control study design was used within the pro-
spective Lupus-Cruces cohort. The local institutional reviewPage 1 of 8
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informed consent (study code CEIC E08/21), in compliance
with the Helsinki Declaration.
All patients fulfilling the updated American College of Rheu-
matology criteria for the classification of SLE [10] on attending
the Internal Medicine Department, Hospital de Cruces – a ter-
tiary teaching center associated with the University of the
Basque Country – have been included in the ongoing pro-
spective, observational study. Patient data since 1973 have
been included in the database. Patients on active follow-up
give informed consent to include their data in our records. The
time of inclusion in the cohort was the point when four Ameri-
can College of Rheumatology criteria were first met. This was
also the time zero of follow-up.
Patients are regularly assessed every 3 months, although the
course of the disease may modify this schedule. Clinical and
immunological variables, including current treatments and
occurrence of major complications, such as infections, are
recorded in a standardized protocol and incorporated into the
database at every follow-up visit. The Systemic Lupus Interna-
tional Collaborating Clinics Damage Index (SDI) has been reg-
ularly used to quantify the presence of irreversible organ
damage [11]. The Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) 2 K was used to measure lupus activity
[12]. Antimicrobial prophylaxis has not been used in our
cohort. Likewise, regular pneumococcal vaccination has been
indicated only recently.
Study endpoint
The endpoint of the present study is the occurrence of major
infections, defined as those that are disseminated (septi-
cemia), affecting deep organs (pneumonia, pyelonephritis,
endocarditis, meningitis), requiring hospital admission for
treatment (severe soft tissue infection, disseminated Varicella
zoster) or causing death. The diagnosis of infection was
always made by our team according to clinical, microbiological
and imaging criteria.
Statistical analysis
To overcome a potential immortal treatment bias – that is, the
decreased possibility of patients with an early final event
receiving the study drug, thus spuriously increasing its protec-
tive effect [13] – we identified patients with major infections
(cases) and selected two control individuals (without any
major infection) per case, matched for the time of follow-up
until the event (± 1 year) and the age at diagnosis. Baseline
data for the whole cohort and for the sample included in the
case–control study were analyzed in order to prevent a selec-
tion bias.
The frequency, type and causal agent (if known) of major infec-
tions were described. Potential predictors of infection
included variables with a possible relation to infection in previ-
ous studies, markers of SLE activity and irreversible organ
damage and variables with a known prognostic influence in
SLE: sex, treatment with antimalarials, prednisone, azathio-
prine, cyclophosphamide, methotrexate, mycophenolate,
cyclosporine or any immunosuppressive drug within 3 months
previous to the study point; dose of prednisone (mg/day) at
the study point; active lupus nephritis, lung involvement
(defined as either active disease or residual restrictive dam-
age) and thrombocytopenia at any time before and at the study
point; hypoclomplementemia C3/C4 and leukopenia at the
study point; presence of anti-DNA and antiphospholipid anti-
bodies (aPL) according to Sapporo criteria [14] at any time
before the study point; SLEDAI at SLE diagnosis and at the
study point; and the SDI at the first 6 months after the diagno-
sis of SLE. Age at diagnosis of SLE was excluded from the
analysis due to the age-matched case–control design of the
study. The study point was defined as the moment of suffering
the first major infection in the cases and the last visit of follow-
up in the controls.
The chi-squared test with Yates' correction, the Student t test
and the Mann–Whitney U test were used for statistical com-
parisons of categorical, normally and non-normally distributed
variables, respectively. In order to identify the independent
predictors of major infections, all variables with P < 0.20 in the
univariate analysis were entered into a binary logistic regres-
sion model with sequential elimination of nonsignificant varia-
bles. Interactions between the variables in the final model were
tested and those resulting significant were added as further
adjustment variables. The goodness of the final model was
tested by calculating the area under the receiver operating
characteristic curve. All of the statistical calculations were car-
ried out using the statistical software SPSS 11.0.4 for Mac
OS X (SPSS Inc., Chicago, IL, USA).
Results
Demographic data
Two hundred and eighty-four patients were included in the
cohort at the time of this study. Two hundred and fifty patients
(88%) were women and 282 (99%) were white. The mean
(standard deviation) age at diagnosis was 36 (16) years. One
hundred and ninety-seven patients (70%) were ever treated
with antimalarials, 238 (84%) with prednisone and 126 (44%)
with immunosuppressive drugs. Two hundred and ten patients
(74%) had no early damage, 66 patients (23%) had a SDI of
1 to 2 and eight patients (3%) had SDI >2.
Two hundred and forty-nine patients (83 cases and 166 con-
trols) were selected from the cohort for inclusion in the nested
case–control analysis. Two hundred and twenty-three patients
(90%) were women and 247 (99%) were white. The mean
(SD) age at diagnosis was 36.2 (18) years for cases and 36.6
(16) years for controls (P = 0.84). The mean (SD) follow-up
was 8.33 (7) years and 9.7 (7) years, respectively (P = 0.13).
One hundred and seventy-six patients (70%) were everPage 2 of 8
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116 (46%) with immunosuppressive drugs. One hundred and
eighty-one patients (72%) had a SDI of 0, 60 patients (24%)
had a SDI of 1 to 2 and seven patients (3%) had SDI >2. The
subgroup selected for the case–control study was thus fully
representative of the whole cohort.
Frequency and types of major infections
Eighty-three patients (29% of the cohort) suffered at least one
major infection. Fifty-five patients (66%) suffered one infec-
tion, 22 patients (27%) suffered two infections, five patients
(6%) suffered three infections and one patient suffered nine
major infections. The 83 infections analyzed in this study are
detailed in Table 1. Eleven of these 83 infections (13%) were
nosocomial.
The causal agent of infection was established in 43 cases
(Table 2). Escherichia coli, Staphylococcus aureus, Mycobac-
terium tuberculosis and Streptococcus pneumoniae were the
most frequent isolates. No cases of Pneumocystis jivorecii
(formerly Pneumocystis carinii) were seen in our cohort,
despite the fact that prophylaxis with cotrimoxazole has not
been used. Four patients received pneumococcal vaccine,
none of whom had a major infection.
Eight patients died as a consequence of infection: pneumonia
was the cause of death in four cases, bacteremia with septic
shock in three cases and peritonitis in one case.
Predictors of major infection
Results of univariate analysis are presented in Table 3. Several
clinical, immunological and therapeutic variables were associ-
ated with major infections: lung and renal involvement at or
previous to the study point, leukopenia at the study point, aPL-
positivity and treatment with prednisone within 3 months pre-
vious to the study point. The dose of prednisone received was
also related to the risk of infection. Treatment with antimalar-
ials, on the other hand, showed a strong inverse association
with major infections. Treatment with any immunosuppressive
drug or with each of the individual agents (azathioprine, meth-
otrexate, cyclophosphamide, mycophenolate or cyclosporine)
did not confer a higher risk of suffering a major infection. Like-
wise, the presence of early damage was not associated with
the occurrence of major infections.
The logistic regression analysis largely reduced the number of
predictors of major infections. Lung involvement at the study
point (odds ratio (OR) = 3.90, 95% confidence interval (95%
CI) = 0.99 to 15.2), aPL positivity (OR = 2.50, 95% CI = 1.25
to 5.01) and the dose of prednisone at the study point (OR =
1.11, 95% CI = 1.05 to 1.17) increased the risk of infection,
whilst antimalarials retained their protective effects against
infection after adjustment (OR = 0.09, 95% CI = 0.05 to
0.18). The remaining independent variables entered into the
regression did not show a significant independent effect. The
ORs for the significant variables did not differ between the ini-
tial model and the final model: 2.25 and 3.90 for lung involve-
ment, 2.21 and 2.50 for aPL, 1.10 and 1.11 for prednisone
dose, and 0.09 and 0.09 for antimalarials, respectively.
The interactions between the significant independent varia-
bles were tested. Only interactions between antimalarials and
aPL (P = 0.016) and between the dose of prednisone and aPL
Table 1
Frequency of major infections (n = 83)
Number of cases %
Pneumonia 34 41
Bacteremia 20 24
Cellulitis and skin abscess 8 10
Tuberculosis 6 7
Meningitis–encephalitis 5 6
Pyelonephritis 4 5
Abdominal infections 3 4
Esophageal candidiasis 1 1
Osteomyelitis 1 1
Disseminated Varicella 1 1
Table 2
Causal agents of major infections
Microorganism Number of cases %
Escherichia coli 7a 16
Staphylococcus aureus 6a 14
Mycobacterium tuberculosis 6 14
Streptococcus pneumoniae 5 12
Salmonella 4 9
Psuedomonas aeruginosa 3 7
Candida albicans 3 7
Neisseria meningitides 2 5
Varicella Zoster virus 2 5
Campylobacter 1 2
Legionella 1 2
Herpes simplex virus 1 2
Serratia 1 2
Staphylococcus epidermidis 1 2
Aspergillus 1 2
aOne patient suffered a combined septicemia by E. coli and S. 
aureus.Page 3 of 8
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entered into the final logistic regression model, aPL was no
longer significant. The other three variables retained the
degree of statistical significance without relevant modifica-
tions in the magnitude of their effect on major infections (see
Table 4). The area under the receiver operating characteristic
curve of this model was 0.88 (95% CI = 0.83 to 0.92). The
inclusion of the continuous variable of time (months) on anti-
malarials instead of the categorical variable of treatment with
antimalarials rendered similar results in the final model (OR =
0.991, 95% CI to 0.984 to 0.999, P = 0.018).
Influence of disease severity on antimalarial treatment 
and its effect on major infections
Several variables related with disease severity were compared
among antimalarial users and nonusers. Patients with antima-
larial treatment were younger at diagnosis, less likely to have
suffered nephritis and leukopenia, and were receiving myco-
phenolate mofetil in a lower proportion at the study point. Like-
wise, they had accrued less early damage than antimalarial
nonusers (Table 5). When these variables were added to the
logistic regression final model, the adjusted OR of suffering a
Table 3
Univariate analysis
Major infection (n = 83) No major infection (n = 166) P value
Female sex 73/83 (88) 150/166 (90) 0.70
Nephritis at study point 15/83 (18) 10/166 (6) <0.01
Previous nephritis 34/83 (41) 39/166 (23) <0.01
Thrombocytopenia at study point 6/83 (7) 7/166 (4) 0.50
Previous thrombocytopenia 19/83 (23) 27/166 (16) 0.27
Lung disease at study point 12/83 (14) 6/166 (4) <0.01
Previous lung disease 13/83 (15) 8/166 (5) <0.01
Leukopenia at study point 32/83 (39) 23/166 (14) <0.01
Low complement at study point 36/81 (44) 52/163 (32) 0.08
Anti-DNA antibodies 61/83 (73) 102/166 (61) 0.08
Antiphospholipid antibodies 43/83 (52) 57/166 (34) 0.01
SDI = 0 57/83 (69) 125/166 (75)
SDI = 1 to 2 22/83 (26) 38/166 (23) 0.29
SDI >2 4/83 (5) 3/166 (2)
SLEDAI at diagnosis 10 (1 to 25) 9 (1 to 22) 0.23
SLEDAI at study point 4 (0 to 24) 3 (0 to 21) 0.15
SLEDAI at diagnosis >12 25/81 (31) 33/163 (20) 0.09
SLEDAI at study point >12 5/81 (6) 7/163 (4) 0.74
Antimalarials 18/83 (22) 128/166 (77) <0.01
Months on antimalarials 0 (0 to 300) 24 (0 to 192) <0.01
Azathioprine 16/83 (19)a 20/166 (12) 0.18
Methotrexate 2/83 (3) 13/166 (8) 0.12
Cyclophosphamide 3/83 (4) 2/166 (1) 0.42
Mycophenolate 1/83 (1) 5/166 (3) 0.66
Cyclosporine 3/83 (2)a 4/166 (5) 0.34
Any immunosuppressor 23/83 (30) 44/166 (26) 0.96
Prednisone 62/83 (75) 90/166 (54) <0.01
Prednisone dose (mg/day) 7.5 (0 to 90) 2.5 (0 to 60) <0.01
Data presented as n/N (%) or median (range). SDI, Systemic Lupus International Collaborating Clinics Damage Index; SLEDAI, Systemic Lupus 
Erythematosus Disease Activity Index. aTwo patients were taking combined treatment with azathioprine and cyclosporine.Page 4 of 8
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Table 4major infection for antimalarial users was 0.070 (95% CI =
0.030 to 0.155), thus remaining largely unchanged (Table 6).
Discussion
Our study showed that one-third of lupus patients developed
serious infections during follow-up. Common bacteria, such as
E. coli, Staphylococcus and S. pneumoniae were the most fre-
quent isolates. Several clinical, immunological and therapeutic
variables showed association with the risk of suffering major
infections. Only three variables, however, had a significant
independent effect: lung disease, dose of prednisone and
treatment with antimalarials at the study point, the latter show-
ing a strongly protective effect.
Logistic regression, final model (dependent variable, major infection)
Variable Odds ratio 95% confidence interval
Lung involvement at study point 4.41 1.06 to 18.36
Prednisone dose (mg/day) 1.12 1.04 to 1.19
Antimalarials 0.06 0.02 to 0.18
Antiphospholipid antibodies 1.88 0.66 to 5.32
Antiphospholipid antibodies × antimalarials 2.21 0.52 to 9.33
Antiphospholipid antibodies × prednisone dose 0.98 0.88 to 1.11
Antiphospholipid antibodies × antimalarials and antiphospholipid antibodies × prednisone dose are interaction variables.
Table 5
Clinical characteristics according to treatment with antimalarials at the study point
Antimalarials P value
Yes (n = 146) No (n = 103)
Age at diagnosis (years) 34 (14) 40 (18) <0.01
Female sex 131/146 (89) 63/103 (86) 1.00
Nephritis ever 35/146 (24) 50/103 (48) <0.01
Lung involvement ever 11/146 (7.5) 13/103 (12.6) 0.26
Thrombocytopenia ever 24/146 (16) 17/103 (26) 0.08
Leukopenia ever 94/146 (64) 85/103 (82) <0.01
Anti-DNA antibodies ever 96/146 (66) 67/103 (65) 1.00
Low complement at study point 48/143 (34) 40/101 (40) 0.40
Prednisone at study point 89/146 (61) 63/103 (62) 1.00
Azathioprine at study point 18/146 (12) 18/103 (18) 0.34
Cyclophosphamide at study point 2/146 (1) 3/103 (3) 0.69
Methotrexate at study point 12/146 (8) 3/103 (3) 0.144
Mycophenolate at study point 6/146 (45) 0/103 (0) 0.04
SDI = 0 121/146 (83) 61/103 (59)
SDI = 1 to 2 25/146 (17) 35/103 (34) 0.001
SDI >2 0/146 (0) 7/103 (7)
SLEDAI at diagnosis 9 (1 to 22) 9 (2 to 25) 0.94
SLEDAI at study point 4 (0 to 21) 3 (0 to 24) 0.84
SLEDAI at diagnosis >12 33/143 (23) 25/101 (25) 0.88
SLEDAI at study point >12 6/143 (4) 6/101(6) 0.75
Data presented as mean (standard deviation), n/N (%) or median (range). SDI, Systemic Lupus International Collaborating Clinics Damage Index; 
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.Page 5 of 8
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well established. Immunosuppressive drugs have increased
the frequency of infections in only a small proportion of studies
[4,8,9]. Treatment with steroids has been identified as a risk
factor in several studies [4,6,8,9], but not in all series [2,3,5,7].
Renal disease, despite being associated with infections in the
univariate analysis in some series, has not retained the statisti-
cal significance in the multivariant analysis [5,6]. Only the
series of the Hopkins Lupus Cohort found an independent
effect of serum creatinine on the rate of hospitalizations due to
infection [7]. Likewise, low complement levels have been sig-
nificant independent predictors in three studies [7,8,15]. A
SLEDAI score higher than 12 at diagnosis has also been
found to increase the risk of infection in one recent study [15].
It is thus a difficult task to identify lupus patients at high risk of
serious infectious complications. The inclusion in some stud-
ies of patients with both minor and major infections [3,6,9]
complicates the interpretation of results. The introduction of
ever variables and at the time of infection variables, depending
on the studies, also adds noise to the conclusions. In addition,
many variables (lupus activity, renal disease, low complement,
treatment with steroids and immunosuppressive drugs) are
intimately related with each other in clinical practice, and thus
their relative weight and interactions are difficult to ascertain,
even with multivariate analysis.
Our study could somewhat clarify the clinical profile of patients
prone to suffering serious infections with the potential to influ-
ence the prognosis of SLE. The nested case–control design,
matched for age and time to event, reduces the possibility of
an immortal treatment bias [12]. We analyzed clinical and
immunological variables that could have an effect on immunity
(leukopenia, lupus nephritis, drug therapy, complement levels),
could reflect lupus activity (SLEDAI score, anti-DNA antibod-
ies, lupus nephritis, lung disease, leukopenia, thrombocytope-
nia, drug therapy) and/or have known prognostic significance
(sex, aPL, lupus nephritis, lung involvement, leukopenia, throm-
bocytopenia, early damage). Treatment variables were
recorded in close temporal relationship with the study point.
In the present study, the prednisone dose at the time of the
event had a facilitating effect on infections, in line with data
coming from other series [4,6,8,9]. It is noteworthy that the
median dose of patients with major infections was only 7.5
mg/day. According to the results of the logistic regression,
each increase of 10 mg/day prednisone multiplied by 11 the
risk of suffering a serious infection. Every effort should there-
fore be made to limit both the dose and the time of exposure
to steroids of lupus patients, also taking into account the close
relation of irreversible damage and prednisone use [16]. On
the contrary, no individual immunosuppressive drug or treat-
ment with any of them increased the risk for serious infections.
This apparent paradox could be explained by the low numbers
of patients on cyclophosphamide, which is usually given in our
unit as low-dose pulses, with a lesser frequency of infectious
complications [17]. We also excluded minor infections, such
as nondisseminated herpes zoster and minor urinary tract
infections, that have been associated with immunosuppres-
sive drugs like azathioprine, cyclophosphamide and meth-
otrexate [18,19]. The association between lung disease and
infection in our cohort could be explained by the frequent
occurrence of serious respiratory infections in patients with
restrictive disease (six out of 14 patients). Noteworthy, com-
plement levels or the SLEDAI score did not modify the risk of
major infection of our patients [15].
Table 6
Logistic regression, adjustment for confounders related with antimalarial treatment (dependent variable, major infection)
Variable Odds ratio 95% confidence interval
Lung involvement at study point 3.11 0.79 to 12.31
Prednisone dose (mg/day) 1.10 1.04 to 1.17
Antimalarials 0.07 0.03 to 0.15
Age at diagnosis 0.99 0.97 to 1.01
Leukopenia ever 1.99 0.82 to 4.82
Nephritis ever 1.61 0.72 to 3.64
Mycophenolate at study point 1.52 0.15 to 15.40
SDI = 0 Reference
SDI = 1 to 2 0.42 0.18 to 1.00
SDI > 2 0.22 0.03 to 1.65
SDI, Systemic Lupus International Collaborating Clinics Damage Index.Page 6 of 8
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that patients taking antimalarials were 16 times less likely to
suffer a major infection. From the pharmacological point of
view, this effect is not surprising. Originally synthesized as
antiparasitic agents, these drugs have a wide range of antimi-
crobial effects [20]. In vitro activity against bacteria (Troph-
eryma whipplei, S. aureus, Legionella pneumophila,
Francisella tularensis, Mycobacterium spp., Salmonella typhi,
E. coli, Borrelia burgdorferi), fungi (Histoplasma capsulatum,
Cryptococcus neoformans, Aspergillus fumigatus) and
viruses (including human immunodeficiency virus) has been
reported [20]. Antimalarials interfere with invasion and inter-
nalization of E. coli into host cells [21]. Clinical studies have
established the combination doxycycline plus hydroxychloro-
quine (HCQ) as the standard treatment for chronic Q fever
[20]. Likewise, combination treatment with HCQ, OH car-
bamide and didanosine reduces the human immunodeficiency
virus load, having been proposed as a cheaper alternative for
the treatment of AIDS [22].
The antibacterial effects of antimalarials are mediated by pH-
dependent iron deprivation and by increasing the phagolyso-
somal pH, both inhibiting the growth of intracellular organisms
[20]. Likewise, the antiviral effects are related to increasing the
lysosomal pH, which disrupts hydrolases and inhibit the post-
translational modification of newly synthesized proteins [23].
Two previous studies in patients with lupus suggest the pro-
tective effect of antimalarials against infection. Sisó and col-
leagues, in a retrospective cohort study of patients with lupus
nephritis, found a lower frequency of infections among those
previously treated with antimalarials [24]. Bultink and col-
leagues, in a study designed to analyze the effect of the defi-
ciency of functional mannose-binding lectin, found that
treatment with HCQ was protective of major infections, with
an adjusted OR (OR = 0.05, 95% CI = 0.01 to 0.23) very sim-
ilar to that obtained in the present study [5]. The authors attrib-
uted this association, however, to the presumed lesser severity
of lupus in patients taking HCQ. In addition, in 1996
Podrebarac and colleagues reported two cases of P. carinii
pneumonia in patients with SLE treated with high-dose ster-
oids shortly after discontinuation of HCQ [25]. We believe that
our study confirms the antimicrobial effects of antimalarials,
which can be actually an additional reason for the increased
survival seen in SLE patients taking these drugs [24,26,27].
Our study has the main limitation of the observational design
– the specific treatment of each patient was therefore not ran-
domized, but rather decided on clinical grounds. In fact,
patients given antimalarials were younger and had less severe
disease, with a lower frequency of nephritis, leukopenia and
early irreversible damage. When these adjustment variables
were added to the regression model, however, the protective
effect of antimalarials on the occurrence of major infections
remained unchanged.
Conclusions
The treatment received by the patient is the most important
determinant of the risk of serious infections. Prednisone
should therefore be used with caution, and maintenance
doses above 5 mg/day are best avoided. In addition, treatment
with HCQ would be indicated in all patients with SLE without
contraindications, given the excellent safety profile and the
wide range of long-term beneficial effects, including the poten-
tial protection from serious infections [28].
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